✦ LIBER ✦

Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia

✍ Scribed by Kelly, Kevin R.; Shea, Thomas C.; Goy, André; Berdeja, Jesus G.; Reeder, Craig B.; McDonagh, Kevin T.; Zhou, Xiaofei; Danaee, Hadi; Liu, Hua; Ecsedy, Jeffrey A.; Niu, Huifeng; Benaim, Ely; Padmanabhan Iyer, Swaminathan

Book ID: 121586530
Publisher: Springer US
Year: 2013
Tongue: English
Weight: 542 KB
Volume: 32
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-013-0050-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An exploratory phase 2 study of investig

An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes

✍ Goldberg, Stuart L.; Fenaux, Pierre; Craig, Michael D.; Gyan, Emmanuel; Lister, 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 329 KB

Phase II Study of Alisertib, a Selective

Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas

✍ Friedberg, J. W.; Mahadevan, D.; Cebula, E.; Persky, D.; Lossos, I.; Agarwal, A. 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 234 KB

A phase I/II study examining pentostatin

A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin’s lymphoma

✍ Carl R. Willis; Amy Goodrich; Kathy Park; Jamie K. Waselenko; Margaret Lucas; Am 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 114 KB

A Phase I and Pharmacodynamic Study of A

A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis

✍ Foran, James; Ravandi, Farhad; Wierda, William; Garcia-Manero, Guillermo; Versto 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 550 KB

379 A first in human phase I study of th

379 A first in human phase I study of the proteasome inhibitor CEP-18770 in patients (pts) with advanced solid tumors, non-Hodgkin's lymphomas (NHL) and multiple myeloma (MM)

✍ C. Sessa; G. Martinelli; D. Hess; A. Delmonte; C. Noberasco; S. Sammassimo; E. G 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Immunotherapy with FBTA05 (Bi20), a trif

Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial

✍ Raymund Buhmann, Stanglmaier Michael, Hess Juergen… 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 328 KB